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Phe Combined Use of Ibutilide
s an Active Control With Intensive
lectrocardiographic Sampling and Signal
veraging as a Sensitive Method to Assess the
ffects of Tadalafil on the Human QT Interval
harles M. Beasley, JR, MD,* Malcolm I. Mitchell, MBBS, MFPM,† Alex A. Dmitrienko, PHD,*
effrey T. Emmick, MD, PHD,* Wei Shen, PHD,* Timothy M. Costigan, PHD,* Alun W. Bedding, BS,†
ichael A. Turik, MD,‡ Arash Bakhtyari, MBCHB, FRCS,§ Margaret R. Warner, PHD, DVM,*
eremy N. Ruskin, MD, Louis R. Cantilena, JR, MD, PHD¶ Robert A. Kloner, MD, PHD#
ndianapolis, Indiana; Windlesham and Merthyr Tydfil, United Kingdom; Boston, Massachusetts;
ethesda, Maryland; and Los Angeles, California
OBJECTIVES This study was designed to evaluate effects of tadalafil, a phosphodiesterase-5 inhibitor used
for the treatment of erectile dysfunction (ED), on the QT interval.
BACKGROUND Cardiovascular disease is common in men with ED. Men with cardiovascular disease and ED
may have decreased cardiac repolarization reserve.
METHODS Effects of tadalafil (100 mg by mouth), ibutilide (0.002 mg/kg intravenously), and placebo on
the QT interval in healthy men were compared (placebo and tadalafil [n  90], with a subset
[n  61] receiving all treatments; mean age 30 years, range 18 to 53 years). Electrocardio-
graphic sampling was done for two days before treatment and on treatment days. The QT was
corrected for RR interval with five correction methods, including an individual correction
(QTcI). Plasma concentrations of tadalafil were measured to evaluate concentration-QT
effect relationships.
RESULTS At the time corresponding to maximum plasma concentration of tadalafil, the mean difference
in the change in QTcI between tadalafil and placebo was 2.8 ms; tadalafil was equivalent to
placebo (a priori, upper limit of 90% confidence interval 10 ms [actual  4.4 ms]; post hoc,
upper limit of 95% confidence interval 5 ms [actual  4.8]). The active control, ibutilide,
significantly increased QTcI by 6.9 and 8.9 ms compared with tadalafil and placebo,
respectively. Similar statistical results were obtained with four additional QT correction
methods. No subject had a QTcI 450 ms or an increase in QTcI 30 ms with any
treatment.
CONCLUSIONS Based on the a priori statistical test of equivalence, placebo and high-dose tadalafil produced
equivalent effects on the QT interval. This study reliably discerned 5- to 10-ms changes in
corrected QT in the ibutilide active control group. (J Am Coll Cardiol 2005;46:678–87)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.036© 2005 by the American College of Cardiology Foundation
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cadalafil, a phosphodiesterase-5 (PDE5) inhibitor, is an
ffective treatment for erectile dysfunction (ED) (1). The
revalence of heart disease is high among men with ED
2,3). Patients with heart disease may have reduced cardiac
epolarization reserve (4) and be at increased risk for
rrhythmia when taking medications that prolong ventric-
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arner are employees and stockholders of Eli Lilly and Company. Dr. Ruskin is a
onsultant to Eli Lilly, Pfizer, Millennium, and CV Therapeutics. Dr. Cantilena, Jr.,
s a consultant to Eli Lilly. Dr. Kloner is a speaker and consultant for Bayer GSK,
illy ICOS, and Pfizer; a consultant for Schering Plough and Palatin/King Pharma-
euticals; and has research support from Lilly ICOS.n
Manuscript received June 3, 2004; revised manuscript received April 28, 2005,
ccepted May 3, 2005.lar repolarization. Because many patients treated for ED
ill have heart disease, the effects of tadalafil on ventricular
epolarization were evaluated.
See page 688
Although there is an association between increases in the
T interval and potentially lethal ventricular arrhythmias
e.g., Torsades de Pointes) (4,5), there is debate concerning
hat constitutes a clinically relevant increase in the QT
nterval (5,6). The cardiovascular adverse events reported
fter regulatory approval of terfenadine and cisapride (6–9)
ave contributed to ongoing efforts at national (U.S. Food
nd Drug Administration) and international (Committee
or Proprietary Medicinal Products and International Com-
ittee on Harmonization) levels to develop standards for
linical trials designed to demonstrate an “absence of sig-
ificant effect” on ventricular repolarization during new
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August 16, 2005:678–87 Tadalafil and the QT Intervalrug development (9 –11). Late-phase clinical trials
esigned to establish this absence of effect have been
ncreasingly requested by the U.S. Food and Drug Admin-
stration, even when results from pre-clinical studies or
outine phase I to III clinical trials have shown no evidence
or drug-induced delays in ventricular repolarization (9,10).
uch studies have been deemed necessary in order to
xplicitly inform the prescriber that a medication is free of
ffects on ventricular repolarization. These studies have
eceived particular attention when the medical condition
nder treatment is not considered life threatening (e.g.,
ommon allergies) and/or when the patient population
nder treatment may be particularly sensitive to adverse
onsequences of delays in ventricular repolarization (e.g.,
atients post-myocardial infarction).
Because many factors influence the QT interval and its
easurement, the optimal QT study has not been estab-
ished (5). Moreover, changes of up to 5 ms occur in the
orrected QT interval (QTc) with placebo treatment alone
12,13), and drugs that increase the risk of sudden cardiac
eath may produce only slightly greater increases (5 to 10
s) in the QTc compared with placebo under conditions of
ormal use (12,13). Any increase in the QTc 10 ms is
hought to definitely increase the risk of Torsades de
ointes, and some suggest that increases in the range of 5 to
0 ms may impart some risk (14). Therefore, when drug
ffects on the QT interval are assessed, the changes of
nterest can be quite small relative to the precision of
easurement (5,13). To prove a hypothesis that states that
test drug is equivalent to placebo with respect to influence
n QT, it is necessary to demonstrate the assay sensitivity of
he study with a treatment arm that produces a statistically
ignificant increase in QT that approximates the smallest
ifference of interest between placebo and test drug. Such a
tudy must maintain subject safety while intentionally
lightly prolonging ventricular repolarization.
We report the results of a study comparing the effects of
lacebo, ibutilide (active control), and tadalafil 100 mg
five-fold maximum therapeutic dose) on the QT interval in
ealthy men using methods sufficiently sensitive to detect
Abbreviations and Acronyms
CI  confidence interval
ECG  electrocardiogram
ED  erectile dysfunction
HERG  human ether-a-go-go-related gene
HR  heart rate
MUSE  Marquette Universal System for
Electrocardiography
PDE5  phosphodiesterase-5
QTc  corrected QT
QTcB  corrected QT (Bazett corrected)
QTcI  corrected QT (individual corrected)
Tmaxh  time of maximum concentration of
tadalafil for each subjectean changes in QTc of 5 to 10 ms. The active control, (butilide, prolongs ventricular repolarization by blocking the
apid component of the delayed rectifier potassium current
nd also by activating a slow inward current carried largely
y sodium (15). Ibutilide is used intravenously to terminate
trial flutter/fibrillation and has desirable characteristics as
n active control because of its relatively short half-life and
ts ability to evoke a dose-related increase in the QT interval
15).
ETHODS
opulation. Subjects were healthy men (age 18 to 53 years)
ith a body mass index of 19 to 29 kg/m2. Laboratory values
ere normal or with minor deviations that were judged not
linically important. Subjects were free of family/personal
istory of congenital long QT syndrome; sudden cardiac
eath; syncope; heart rate (HR) 100 beats/min or 40
eats/min; supine or standing systolic or diastolic blood
ressure 140 mm Hg or 90 mm Hg, respectively; and
ecrease in systolic blood pressure of 20 mm Hg or HR
ncrease of 20 beats/min when changing from supine to
tanding. Electrocardiograms (ECGs) were free of conduc-
ion defect, rhythm disturbance (except for sinus arrhythmia
r isolated premature atrial complexes/premature ventricular
omplexes), biphasic T waves, U waves that were more than
ne-third of the preceding T waves, PR interval 200 ms,
RS 110 ms, and Bazett-corrected (16) QT interval
QTcB) 440 ms.
Excessive methylxanthine use (investigator judgment),
moking 5 cigarette equivalents/day, alcohol intake 28
/week (1.5 oz of 80 proof spirits equivalent), positive
rug abuse screen, prescription medication two weeks be-
ore first treatment, or over-the-counter medication (includ-
ng herbal products) one week before first treatment (except
itamin supplements and acetaminophen) were exclusion-
ry. Alcohol one week prior; methylxanthine, grapefruit, or
moking three days prior; and any alteration in the amount
f customary exercise four days prior and through each
bservation period were prohibited.
Each subject gave informed written consent and the study
as approved by institutional review committees. The study
as conducted in accordance with the Declaration of
elsinki and Guidelines for Good Clinical Practice.
rimary objectives. The study had three primary objec-
ives: 1) to test that tadalafil is equivalent to placebo with
espect to changes in the QT interval corrected using a
ubject-specific individual correction (QTcI) (12,17); and to
est that, 2) placebo and 3) tadalafil produce significantly
maller increases in the QTcI compared to the active control
butilide (when ibutilide increases QTcI by 5 to 10 ms).
tudy design: treatments. Subjects were assigned by ran-
om allocation to receive one of two sequences of treatment:
ither a two-way crossover (placebo, tadalafil) or a three-
ay crossover (placebo, tadalafil, ibutilide) (Fig. 1). The
umber of subjects assigned to each sequence of treatments
placebo-tadalafil  32; placebo-tadalafil-ibutilide  67)
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Tadalafil and the QT Interval August 16, 2005:678–87as sufficient to achieve the total number of subjects treated
ith both drugs for the three statistical drug pair compar-
sons specified by the prospective statistical analysis plan
total completed: placebo vs. tadalafil  90; tadalafil vs.
butilide 62; placebo vs. ibutilide  61) (see “Sample size”
ection and Fig. 1). The order of treatment administration
ithin the two treatment sequences was also randomized.
ach treatment was administered on a separate day and
here was a washout period of at least 12 days between each
reatment.
For the purpose of analysis (i.e., comparison of tadalafil
s. placebo), the data from subjects receiving only placebo
nd tadalafil were combined with the placebo and tadalafil
ata from subjects receiving all three treatments (analysis
ncluded all subjects who received placebo and tadalafil)
Fig. 1). Those subjects receiving all three treatments were
ncluded in the ibutilide versus placebo and ibutilide versus
adalafil comparative analyses because these subjects re-
eived ibutilide and placebo as well as ibutilide and tadalafil.
A single oral dose of tadalafil 100 mg and placebo was
tudied. For tadalafil, 100 mg is five times the maximum
pproved dose (i.e., 20 mg given a maximum of once daily).
he dose of ibutilide (0.002 mg/kg intravenously over 10
in) produced an increase in QTcB in the desired range (5
o 10 ms) and was selected on the basis of an open-label
tudy of ibutilide and placebo in a separate cohort of subjects
for real-time patient management, QTcB was used to
nalyze changes in the QT interval). The ibutilide infusion
igure 1. Subject disposition. Subjects were assigned by random allocation
adalafil) or a three-way crossover (placebo, tadalafil, ibutilide). The numbe
lacebo-tadalafil-ibutilide, n 67) was sufficient to achieve the total number
pecified by the prospective statistical analysis plan (total receiving: placebo v
or discontinuation are listed in the Results section. One subject received t
ith tadalafil and placebo). This subject was included in the intent-to-treat
Not included in any of the comparative analyses because subjects did notas stopped if the QTcB interval increased by 12 ms on iwo consecutive ECG readings or by 30 ms on one ECG
eading (13 of 67 ibutilide infusions were stopped early on
he basis of these criteria).
Personnel were blinded to placebo and tadalafil treat-
ents but were not blinded to ibutilide. Treatments were
dministered at either 8 or 10 AM and were administered at
he same time of day across treatments for each subject.
tudy design: ECG recording and assessment. All stud-
es were performed in clinical-pharmacology inpatient set-
ings. For 2 days before placebo or tadalafil dosing (Fig. 2),
aseline ECGs were recorded at 0, 3, 4, 6, 9, 12, and 24 h.
n tadalafil or placebo treatment days, ECGs were re-
orded before dose and at 3, 4, 6, and 24 h after dose. Blood
amples were obtained after recording ECGs to measure
lasma concentrations of tadalafil and tadalafil methylcat-
chol glucuronide (metabolite has no PDE5 inhibitor
ctivity).
For each time point (indicated by an X in Fig. 2), the QT
as calculated as the mean of 10 ECGs. Averaging the
alues from 10 ECGs optimized signal-to-noise ratio and
educed beat-to-beat variations in the QT measurement as
etermined in our pilot open-label study used to select the
ose of ibutilide. The selection of 10 ECGs for the purpose
f signal averaging was based on the premise that the largest
umber of ECGs that could be practically obtained and
ontribute to such signal averaging would provide the most
ccurate signal. The “maximum effect” of ibutilide on QT
as calculated as the mean of 10 ECGs at the end of
eive one of two sequences of treatment, either a two-way crossover (placebo,
ubjects assigned to each sequence of treatments (placebo-tadalafil, n  32;
jects treated with both drugs for the three statistical drug pair comparisons
alafil 90; tadalafil vs. ibutilide 62; placebo vs. ibutilide 61). Reasons
ent with ibutilide and two treatments with placebo (rather than treatment
ide-placebo, tadalafil-placebo, and tadalafil-ibutilide comparative analyses.
ve at least two treatments.to rec
r of s
of sub
s. tad
reatmbutilide infusion (Fig. 2). If the ibutilide infusion was
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August 16, 2005:678–87 Tadalafil and the QT Intervaltopped early, the ECGs recorded in the 10 min following
he termination of the infusion were used to calculate
butilide-induced changes in the QT interval.
Electrocardiograms were collected electronically on
AC5000 machines (GE Medical, Waukesha, Wiscon-
in), sent to a central interpretive site (Cardioanalytics,
lymouth, United Kingdom), and overread by one of three
echnicians and one cardiologist (blinded to all treatments).
he QT interval was measured using median complexes
erived from the full 10 s of recording for each of the 12
eads (using the Marquette Universal System for Electro-
ardiography [MUSE] and the 12SL algorithm). The 12
edian waveforms were then superimposed and aligned
sing a template correction technique (CardioAnalytics).
he QT interval was measured onscreen using 12SL-
enerated markers on the superimposed median waveform
omplexes from the earliest deflection of the Q-wave to the
atest termination of the T-wave across all 12 ECG leads.
he earliest Q-wave deflection and the latest T-wave
ermination could come from separate leads. The QT was
anually remeasured with onscreen calipers to confirm the
ccuracy of the 12SL measurement. If the manual remea-
urement was within 5 ms of the 12SL measurement, the
2SL measurement was deemed accurate (if 5 ms the
anual measurement was used).
The RR interval was determined from the MUSE/12SL-
alculated HR, and the accuracy was verified by manual
easurement. To verify the MUSE/12SL-generated HR, if
he rhythm appeared regular, the technician initially mea-
ured one RR interval, and if the rhythm appeared irregular,
he technician initially measured multiple RR intervals.
his interpretation of the rhythm regularity was a subjective
igure 2. Study design and times of electrocardiogram (ECG) recording.
t 1-min intervals for 10 min (total of 10 ECGs recorded at each time po
y a filled circle, a single 12-lead ECG was recorded for 10 s. Admin
ntravenous ibutilide was unblinded.   10 ECGs obtained at 1-min innterpretation on the part of the technician. This initial sssessment was intended to provide only a first evaluation of
he accuracy of MUSE/12SL-generated HR. If this initial
ssessment resulted in a HR value that differed from the
USE/12SL by 5 beats/min, the technician would mea-
ure all RR intervals in the 10-s ECG recording to calculate
he HR. Of the 34,630 ECGs in the data set, a total of 6
CGs (0.017%) required manual HR correction.
The QT was corrected for RR interval by fitting a linear
odel to all baseline (drug-free) data and using the slope to
onstruct a subject-specific (individual) QT correction for-
ula (QTcI) (12,17).
ample size. Sample size was based on an intrasubject
ariability of 8.7 ms for uncorrected QT interval based on
eview of Phase I studies supporting tadalafil registration.
inety subjects provided 99% power to declare equiva-
ence between tadalafil and placebo with respect to mean
hange in QTcI when equivalence required the upper
imit of the two-sided 90% confidence interval (CI) for
he difference to be 10 ms (a priori definition of
quivalence) and 98% power for the difference to be 5
s. The power was 97% when equivalence required the
pper limit of the two-sided 95% CI for the difference to
e 5 ms (post-hoc definition of equivalence, more
tringent than the a priori definition).
To demonstrate the superiority of tadalafil and placebo to
butilide with respect to mean change in the QTcI, 60
ubjects provided 99% power to detect a mean difference
f 10 ms between treatments with a two-sided significance
evel of 5%, and 87% power to detect a mean difference of
ms with a two-sided significance level of 5%. The a priori
efinition of significant difference was based on a two-sided
ch time point indicated by an X, a 12-lead ECG was recorded for 10 s
or ibutilide treatment days (bottom panel), at each time point indicated
on of oral tadalafil and placebo was double blind and administration of
s; ●  single ECG.At ea
int). Fignificance level of 5% (two-sided 95% confidence interval).
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Tadalafil and the QT Interval August 16, 2005:678–87nalysis of primary outcomes. TADALAFIL VERSUS PLA-
EBO AT TMAXH. For tadalafil and placebo, the change in
TcI was calculated as the change from before dose to
maxh (time of maximum concentration of tadalafil for each
ubject) in two steps: first on baseline days and then on
reatment days (baseline represented the average of two days
f measurements). The change measured on baseline days
as subtracted from the change on treatment days to give
he change in QTcI due to treatment alone (this method
orrected for any diurnal variation in QTcI) (18). The
ifference in QTcI was then calculated as (change after
adalafil)  (change after placebo).
ADALAFIL AND PLACEBO VERSUS IBUTILIDE AT TMAXH.
adalafil and placebo were compared with ibutilide on the
asis of the change from before dose to Tmaxh for tadalafil
nd placebo and the change from before dose to maximum
ffect for ibutilide.
nalysis of secondary outcomes. The changes in QTcI at
, 4, 6, and 24 h post-tadalafil were compared with placebo
sing the analysis described earlier for tadalafil minus
lacebo at Tmaxh.
dditional analyses. Four additional QT correction meth-
ds were applied: Bazett’s (QTcB) (16), Fridericia’s (QTcF)
19), a nonlinear “population-based” formula ([QT/
R0.34]) (QTcP) (20), and a “model-based” formula that
omputed the difference in change in absolute QT between
reatments with RR included as a covariate (QTcM) (21).
The relationships between changes in QTcI and plasma
oncentrations of tadalafil and tadalafil methylcatechol gluc-
ronide (sum of free and bound concentration) were also
nalyzed. Treatment-emergent adverse events were reported
nd were collected based on spontaneous complaints and
pen-ended questioning.
tatistical methods. A mixed-model analysis of variance
as used to analyze differences between treatments with
espect to changes in QTcI with terms for treatment (fixed
ffect), subject (random effect), time (fixed effect), subject by
reatment (random effect), subject by time (random effect),
nd treatment by time (fixed effect) (22). SAS 8.2 software
SAS Institute, Cary, North Carolina) was used for all
tatistical analyses and the mixed models were fit using the
IXED procedure. The relationships between changes in
TcI and plasma concentrations were analyzed by estimat-
ng the slope of a linear regression model and computing the
value.
ESULTS
ubject demographics. Demographics were comparable
mong the intent-to-treat population (Table 1).
ubject disposition. Figure 1 shows that 99 subjects were
andomized (received at least one treatment), with 90
eceiving tadalafil and placebo, 62 receiving tadalafil and
butilide, and 61 receiving placebo and ibutilide (61 subjects
eceived all three treatments). Nine subjects did not com-
lete the study: three because of subject decision, oneecause of an adverse event (fractured ankle, considered
nrelated to study treatment), and five failed to continue to
eet inclusion criteria (low serum calcium [n  2], first-
egree atrioventricular block [n  1], positive drug of abuse
creen [n  1], and QT could not be read accurately owing
o the presence of U waves [n  1]). Subjects that
iscontinued but received one treatment included tadalafil
n  2), placebo (n  1), and ibutilide (n  5); one subject
iscontinued after receiving two treatments (tadalafil and
butilide) (Fig. 1). Additionally, one subject received treat-
ent with ibutilide and two treatments with placebo (rather
han treatment with tadalafil and placebo). This subject was
ncluded in the intent-to-treat ibutilide-placebo, tadalafil-
lacebo, and tadalafil-ibutilide comparative analyses.
ffects of tadalafil, placebo, and ibutilide. The top half of
able 2 shows the baseline mean HR, absolute QT, and
TcI measured before treatment with placebo and tadalafil.
ver a 24-h period (average of 2 days), baseline HR varied
y 4.6 beats/min, absolute QT interval by 9.9 ms, and QTcI
y 3.7 ms. The bottom half of Table 2 shows the effect of
adalafil, placebo, and ibutilide on the mean HR, QT, and
TcI.
The mean differences between treatments at Tmaxhour are
hown in the top half of Table 3. For tadalafil minus
lacebo, the mean difference in the change in QTcI was 2.8
s. The effect of tadalafil was statistically equivalent to
lacebo (both a priori upper 90% CI of 4.4 ms and more
tringent post-hoc upper 95% CI of 4.8 ms did not exceed
ither the a priori 10 ms or more stringent post hoc 5-ms
imits for declaring equivalence). The mean difference for
butilide minus placebo was 8.9 ms and for ibutilide minus
adalafil was 6.9 ms (significantly different; 95% CIs did not
ontain 0). Because the mean difference between ibutilide
nd placebo was significant and 10 ms, this study had the
ensitivity to identify as significant small differences between
reatments in the change in QTcI.
The mean differences in the changes in QTcI for tadalafil
inus placebo from 3 to 24 h post-dosing ranged from 1.1
o 3.5 ms (bottom half of Table 3). The effects of tadalafil
ere statistically equivalent to placebo at all time points
upper 90% and 95% CIs 10 ms).
able 1. Subject Demographics
Tadalafil
(n  93)
Placebo
(n  91)
Ibutilide
(n  67)
ge (yrs, mean  SD) 30  8.8 30  8.7 31  8.5
ody mass index (kg/m2,
mean  SD)
24.7  2.7 24.7  2.7 24.5  2.7
ace, n (%)
White 88 (95%) 86 (95%) 61 (91%)
Black 5 (5%) 5 (5%) 6 (9%)
obacco use, n (%) 23 (25%) 23 (25%) 18 (27%)
lcohol use, n (%) 68 (73%) 68 (75%) 50 (75%)
total of 99 subjects entered the study. The n values represent the intent-to-treat
opulation that received the indicated treatment (subjects were randomized to receive
wo or all three treatments). Tobacco use  1 to 5 cigarettes/day or 3 to 25 g
obacco/week; Alcohol use  1 to 24 U/week (1 U  1.5 oz 80 proof equivalent).Table 4 shows the mean difference between treatments in
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August 16, 2005:678–87 Tadalafil and the QT Intervalhe change in QT interval at Tmaxh using five correction
ethods. The results with our a priori statistical tests
esulted in identical conclusions (i.e., tadalafil is equivalent
o placebo, and ibutilide evoked significantly greater in-
reases in the corrected QT interval compared with placebo
r tadalafil), regardless of the QT correction method em-
loyed. The HR increased slightly after tadalafil and ibuti-
ide compared with placebo and decreased after ibutilide
ompared with tadalafil (Table 3, top). Because Bazett’s
ethod inadequately corrects for changes in HR (23), the
ean treatment differences using Bazett’s correction were
verestimated for the tadalafil-placebo and ibutilide-placebo
omparisons and were underestimated for the ibutilide-
adalafil comparison (Table 4).
ategorical change results. No subject had a QTcI inter-
al 450 ms or an increase in the QTcI interval from
aseline of 30 ms with placebo, tadalafil, or ibutilide
reatment.
ean change in QTcI versus tadalafil plasma concen-
ration. There was no significant relationship between
hanges in the QTcI interval and plasma concentration of
adalafil (slope  0.001; p  0.488) (Fig. 3A) or its
etabolite (slope  0.003; p  0.090) (Fig. 3B).
afety. The treatment-emergent adverse events in 5% of
ubjects when taking tadalafil 100 mg (n  93) were
eadache (76%), back pain (23%), nasal congestion (22%),
yalgia (19%), flushing (16%), pain in limb (13%), dizzi-
ess (11%), arthralgia (10%), spontaneous penile erection
10%), nausea (9%), and eye pain (5%). Headache was
eported by 12% of subjects when taking placebo (n  91).
he adverse events reported for tadalafil 100 mg are
onsistent with those expected after administration of a
DE5 inhibitor (e.g., effects due to mild vasodilation) at a
ose five-fold greater than the maximum therapeutic dose.
ost-hoc analyses. The 95% CI for the 2.8-ms mean
ifference in the change in QTcI at Tmaxh for tadalafil
inus placebo was 0.9 to 4.8 ms (Table 3, top). Tadalafil
as statistically equivalent to placebo based on our a priori
quivalence test (upper limit of 90% CI 10 ms) as well as
ased on the upper limit of 95% CI 5 ms (post hoc).
owever, 2.8 ms represents a significant difference using a
onventional inferential test (95% CI did not contain zero).
2.8-ms increase in QTcI is below the threshold of 10 ms
ecognized as likely to impart some arrhythmic risk as well
s below the 5-ms change often observed with placebo
12,13) and believed to be without meaningful risk.
One subject, randomized to receive all three treatments,
nadvertently received placebo during the tadalafil period.
he inferential conclusions did not change when the data
ere reanalyzed after excluding this subject.
ISCUSSION
adalafil was equivalent to placebo with respect to effects on
entricular repolarization as assessed by the QTc interval.
dditionally, the effect of tadalafil on QTc was significantly Ta
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Tadalafil and the QT Interval August 16, 2005:678–87ess than that of the active control ibutilide. For ibutilide
ompared with placebo (i.e., the prospective evaluation of
he study’s assay sensitivity), the difference in the change in
TcI of 8.9 ms was significant, with the actual sensitivity of
he study (smallest difference that could be found signifi-
ant) being at least as low as 6.5 ms (lower limit of the
5% CI).
This study employed techniques to increase the sensitivity
f detecting any existent signal of QT prolongation. The
tudy is unique in collecting a large number of ECGs (over
4,000) with signal averaging, obtaining intensive baseline
CG sampling, and using intravenous ibutilide as an active
ontrol. The combined use of these methodologies was
ntended to: 1) detect a small change in QTc if such a
hange was occurring; 2) allow a definitive conclusion that a
hange in QTc was not occurring within extremely small
imits, and thus define an absence of change if such were the
ase; and 3) include a means to specify the sensitivity of
etecting the presence or absence of a change in the QTc
nterval. Because this study was designed to demonstrate
bsence of effect (zero difference) within extremely tight
argins (5 ms), we believed that substantial measures would
e necessary to overcome beat-to-beat variability and mea-
able 3. Mean Differences Between Treatments in Change in H
QTcI (ms) QT
adalafil minus placebo (n  90) Tmaxh 2.8 
butilide minus placebo (n  61) Tmaxh 8.9
butilide minus tadalafil (n  62) Tmaxh 6.9 1
adalafil minus placebo (n  90) 3-h 3.3 
adalafil minus placebo (n  90) 4-h 3.1 
adalafil minus placebo (n  90) 6-h 3.5 
adalafil minus placebo (n  90) 24-h 1.1 
hanges () represent mean differences for the comparisons indicated in the first c
tadalafil minus placebo) and the 95% CIs are shown for the ibutilide comparisons. T
as highest for each subject on the actual day of treatment.
Abbreviations as in Table 2.
able 4. Mean Difference Between Treatments in the Change in
QTc Tadalafil
Minus Placebo
QTc Ibutilide
Minus Placebo
QTc
Minus
ndividual 2.8 8.9
opulation 3.5 9.5
azett 6.6 11.5
ridericia 3.5 9.5
odel based 3.3 9.6
he 90% and 95% confidence intervals (CIs) are shown for the mean differences (tad
he specific hour at which the tadalafil plasma concentration was highest for each subject o
QTc  corrected QT.urement error in the QT interval. Although we included
ore replicate ECG measurements than necessary for the
ignal-averaging methodology, at the onset of the study we
id not know and had no basis for predicting the number
equired. The 10 replicate number accomplished the goal
nd also provided us with the basis for determining the
umber of ECGs necessary in a signal averaging process to
vercome variability and measurement error. On the basis of
his study, it is likely that three to six replicate ECGs at each
ime point would be sufficient for adequate signal averaging.
Concerning the protocol design, one must consider the
thics of conducting a study in which subjects are given an
active control” that is known to delay ventricular repolar-
zation and that may impart some risk. An ideal active
ontrol should fulfill several criteria: 1) evoke only small,
eliable increases in the QT interval (5 to 10 ms with small
tandard deviation); 2) produce effects on the QT interval
hat can be controlled in real time; and 3) have a short
harmacokinetic half-life and pharmacodynamic active pe-
iod. Although oral medications that prolong the QT
nterval (e.g., moxifloxacin, sotalol, imipramine) are easy to
dminister, they may not produce mean QT changes in the
esired range, they may result in excessive variability in the
T, and QTcI
)
HR
(beats/min)
QTcI
(CIs)
QT
(CIs)
HR
(CIs)
3.1 (1.2, 4.4)
(0.9, 4.8)
(5.5, 0.7)
(6.2, 1.3)
(1.7, 4.5)
(1.5, 4.7)
1.8 (6.5, 11.2) (1.3, 10.1) (0.2, 3.5)
2.3 (4.6, 9.2) (6.4, 15.4) (4.1, 0.5)
3.5 (1.7, 4.9)
(1.4, 5.2)
(6.3, 0.1)
(6.9, 0.8)
(2.0, 4.9)
(1.7, 5.2)
2.1 (1.5, 4.7)
(1.1, 5.0)
(3.6, 2.8)
(4.2, 3.4)
(0.6, 3.5)
(0.3, 3.8)
3.0 (1.9, 5.2)
(1.6, 5.5)
(3.4, 3.0)
(4.0, 3.6)
(1.5, 4.4)
(1.2, 4.7)
5.7 (0.6, 2.7)
(0.9, 3.0)
(11.3, 4.9)
(12.0, 4.3)
(4.2, 7.1)
(4.0, 7.4)
. The 90% and 95% confidence intervals (CIs) are shown for the mean differences
as the specific hour (of hours 3, 4, or 6) at which the tadalafil plasma concentration
Measured at TmaxH Using Five QT Correction Methods
lide
lafil
CIs Tadalafil
Minus Placebo
CIs Ibutilide
Minus Placebo
CIs Ibutilide
Minus Tadalafil
(1.2, 4.4)
(0.9, 4.8)
(6.5, 11.2) (4.6, 9.2)
(2.0, 5.1)
(1.6, 5.4)
(7.2, 11.8) (4.9, 9.2)
(4.6, 8.7)
(4.2, 9.1)
(8.8, 14.1) (2.5, 7.5)
(1.9, 5.1)
(1.6, 5.4)
(7.2, 11.8) (4.9, 9.2)
(1.7, 5.0)
(1.3, 5.3)
(7.3, 12.0) (4.6, 9.1)
inus placebo) and the 95% CIs are shown for the ibutilide comparisons. Tmaxh wasR, Q
(ms
2.4
5.7
0.9
3.1
0.4
0.2
8.1
olumn
maxh wQTc
Ibuti
Tada
6.9
7.0
5.0
7.1
6.8
alafil m
n the actual day of treatment.
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August 16, 2005:678–87 Tadalafil and the QT Intervalhange in QT across subjects, and their effects cannot be
erminated quickly (24,25). By choosing low-dose ibutilide
s the active control, effects on the QT interval were
ontrolled in real time and began to decline approximately
0 min after stopping the infusion. The dose of ibutilide was
elow the therapeutic dose, but reliably produced the
esired difference from placebo in change in QT across
ubjects (i.e., 8.9 ms). Furthermore, no subject had a QTcI
450 ms or an increase of 30 ms from before infusion in
esponse to ibutilide. These results underscore that ibutilide,
s used, met the criteria for a desirable and safe active
ontrol. Although low-dose ibutilide was not used as an
ctive control, Rodriguez et al. (26) used it to compare the
egree of QT interval prolongation between men and
omen and demonstrated that ibutilide could be used
afely, producing only moderate increases in QTcB.
Limitations of the study included the following: 1) Inclusion
f only healthy men with no known cardiac electrophysiologic
igure 3. Change (tadalafil minus placebo) in the individually correcte
ethylcatechol glucuronide.isk factors. This population was part of the study designecause an active control was administered, it was consistent
ith regulatory guidelines (9,10), and the objective of the study
as to determine if tadalafil had direct effects on ventricular
epolarization in the absence of any disease or drug interac-
ions. 2) The study did not include women. Women are more
ikely than men to develop Torsades de Pointes after receiving
rugs that prolong the QT interval (27,28). 3) The threshold
or use of manually measured heart rate values of5 beats/min
difference between manually measured and MUSE/12SL
easured of 5 beats/min) could result in an error in the
azett-corrected QT interval of over 20 ms in an individual
CG measurement. In this study, six (0.017%) individual
CGs showed such discrepancy between MUSE/12SL and
and measurements (all ECGs were both hand and machine
easured). 4) Both the subject and the physician were un-
linded to the ibutilide treatment (however, the cardiologist
nd technicians reading the ECGs were blinded to all treat-
ents). Ideally, the active control should be fully blinded.
interval (QTcI) versus plasma concentration of tadalafil and tadalafild QTThe equivalent effect of tadalafil and placebo on the QTcI
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Tadalafil and the QT Interval August 16, 2005:678–87ndicates that tadalafil conveys no risk for arrhythmia due to
rolonged ventricular repolarization in healthy men. Al-
hough these results do not definitively prove that changes
n ventricular repolarization would not occur in men with
D and/or cardiovascular disease, the data support and
xtend results from phase II and III tadalafil clinical trials
hat showed no ECG evidence of QT prolongation in
atients with ED from the general population (including
en with ED and comorbid cardiovascular disease and/or
iabetes mellitus) (29).
Furthermore, pre-clinical studies conducted as part of the
ormal course of drug development demonstrated that
ompounds that inhibit PDE5 (i.e., sildenafil citrate,
adalafil, and vardenafil HCl) were not potent blockers of
he human ether-a-go-go-related gene (hERG) channel
e.g., the IC50 for tadalafil was 100 M) (30). Blockade of
ERG channels and reduction of the repolarizing current,
Kr, can be a signal for drugs that cause Torsades de Pointes;
owever, this effect is not specific, because many drugs have
een shown to reduce IKr yet not evoke Torsades de Pointes
6). To our knowledge there have been no explicit cases of
orsades de Pointes for tadalafil, sildenafil, or vardenafil
escribed in published reports.
Critical to the assessment of ventricular repolarization
sing the QT interval is selecting an optimal correction
ethod for HR (12,16,17,19–21,23,31–33). As shown in
able 4, the magnitude of calculated changes in the QTc
nterval varied depending on the correction method applied.
ome methods over- or undercorrect when HR changes
16), and many rely on control populations that differ from
he study population (16,19,20). Malik et al. (12,17,33)
howed that the QT-RR interval relationship varies across
ndividuals and proposed that the optimal correction is
ndividually based. This requires 60 to 100 nontreatment
CGs and distribution of RR values such that a best-fit
orrection can be computed for each subject (assuming the
ithin-subject QT-RR relationship is constant). This
ndividual-based QT correction was used for our primary
nalysis; however, some studies have shown that even within
ndividuals the QT-RR relationship can be variable (18,31).
Because there is risk of arrhythmia when using medica-
ions that prolong the QT interval, definitive studies are
ecessary that accurately and reliably measure drug effects
n ventricular repolarization. Such studies may become the
re-approval standard for medications from various thera-
eutic classes, except for medications where prolongation of
he QT interval is a desired characteristic (some antiar-
hythmic medications), medications where the benefits of
herapy clearly outweigh subtle increases in QTc, or medi-
ations shown to prolong the QTc through routine preap-
roval trials. Our study provides a method to accurately
easure subtle drug-induced increases in the QT interval, if
hey occur, and allows the conclusion of absence of effect, if
uch is the case.
In conclusion, this study combined signal averaging for aarge number of ECGs, intensive baseline ECG sampling, 1nd the use of ibutilide as an active control to increase the
ensitivity of detecting any signal of drug-induced QT
nterval prolongation. The results showed that the effects of
igh-dose tadalafil were equivalent to placebo with respect
o mean changes in the QT interval. This study or some of
ts design characteristics may serve to guide future studies
valuating the effects of drugs on ventricular repolarization.
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